Determinants of the quantity of hepatitis C virus RNA

被引:90
作者
Thomas, DL
Astemborski, J
Vlahov, D
Strathdee, SA
Ray, SC
Nelson, KE
Galai, N
Nolt, KR
Laeyendecker, O
Todd, JA
机构
[1] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[3] New York Acad Med, Ctr Urban Epidemiol Res, New York, NY USA
[4] Bayer Diagnost, Emeryville, CA USA
关键词
D O I
10.1086/315314
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To test the hypothesis that person-to-person variability in blood levels of hepatitis C virus (HCV) RNA can be explained, the quantity of HCV RNA was assessed in 969 persons who acquired HCV infection in the context of injection drug use. Serum HCV RNA levels ranged from 200,000 to >120 million equivalents/mL (the linear range of the assay). The median log(10) HCV RNA level was 0.46 higher in 468 human immunodeficiency virus (HIV)-positive persons than in 501 HIV-negative persons (P < .001), In addition, among HIV-negative persons, lower HCV RNA levels were independently associated with younger age (P < .001), ongoing hepatitis B infection (P = .005), and the absence of needle sharing (P = .02), However, >90% of the person-to-person HCV RNA level variability was not explained by these sociodemographic, environmental, and virologic factors. Additional research is necessary to ascertain what determines the level of HCV RNA in blood.
引用
收藏
页码:844 / 851
页数:8
相关论文
共 46 条
[1]   Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection [J].
Chayama, K ;
Tsubota, A ;
Kobayashi, M ;
Okamoto, K ;
Hashimoto, M ;
Miyano, Y ;
Koike, H ;
Kobayashi, M ;
Koida, I ;
Arase, Y ;
Saitoh, S ;
Suzuki, Y ;
Murashima, N ;
Ikeda, K ;
Kumada, H .
HEPATOLOGY, 1997, 25 (03) :745-749
[2]   Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection [J].
Chu, CM ;
Yeh, CT ;
Liaw, WF .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (07) :2084-2086
[3]   HIGH HEPATITIS-C VIREMIA AND IMPAIRED ANTIBODY-RESPONSE IN PATIENTS COINFECTED WITH HIV [J].
CRIBIER, B ;
REY, D ;
SCHMITT, C ;
LANG, JM ;
KIRN, A ;
STOLLKELLER, F .
AIDS, 1995, 9 (10) :1131-1136
[4]   SURVEY OF MAJOR GENOTYPES AND SUBTYPES OF HEPATITIS-C VIRUS USING RFLP OF SEQUENCES AMPLIFIED FROM THE 5' NONCODING REGION [J].
DAVIDSON, F ;
SIMMONDS, P ;
FERGUSON, JC ;
JARVIS, LM ;
DOW, BC ;
FOLLETT, EAC ;
SEED, CRG ;
KRUSIUS, T ;
LIN, C ;
MEDGYESI, GA ;
KIYOKAWA, H ;
OLIM, G ;
DURAISAMY, G ;
CUYPERS, T ;
SAEED, AA ;
TEO, D ;
CONRADIE, J ;
KEW, MC ;
LIN, M ;
NUCHAPRAYOON, C ;
NDIMBIE, OK ;
YAP, PL .
JOURNAL OF GENERAL VIROLOGY, 1995, 76 :1197-1204
[5]  
DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603
[6]   Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features [J].
De Moliner, L ;
Pontisso, P ;
De Salvo, GL ;
Cavalletto, L ;
Chemello, L ;
Alberti, A .
GUT, 1998, 42 (06) :856-860
[7]   Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection [J].
Enomoto, N ;
Sakuma, I ;
Asahina, Y ;
Kurosaki, M ;
Murakami, T ;
Yamamoto, C ;
Ogura, Y ;
Izumi, N ;
Marumo, F ;
Sato, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (02) :77-81
[8]   Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women [J].
Evans, JS ;
Nims, T ;
Cooley, J ;
Bradley, W ;
Jagodzinski, L ;
Zhou, S ;
Melcher, GP ;
Burke, DS ;
Vahey, M .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (04) :795-800
[9]  
EYSTER ME, 1994, BLOOD, V84, P1020
[10]   LACK OF PROTECTIVE IMMUNITY AGAINST REINFECTION WITH HEPATITIS-C VIRUS [J].
FARCI, P ;
ALTER, HJ ;
GOVINDARAJAN, S ;
WONG, DC ;
ENGLE, R ;
LESNIEWSKI, RR ;
MUSHAHWAR, IK ;
DESAI, SM ;
MILLER, RH ;
OGATA, N ;
PURCELL, RH .
SCIENCE, 1992, 258 (5079) :135-140